| Year |
Title |
Altmetric |
| 2023
|
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years..
Blood Advances.
7:611-619.
2023
|
|
| 2023
|
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.
Blood.
141:168-179.
2023
|
|
| 2023
|
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease..
Journal of Clinical Oncology.
JCO2201203.
2023
|
|
| 2023
|
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center.
Pediatric Blood and Cancer.
70.
2023
|
|
| 2023
|
Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance
2023
|
|
| 2023
|
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
American Journal of Hematology.
98:11-22.
2023
|
|
| 2022
|
Sleep quality and pain in adolescents and young adults with sickle cell disease
2022
|
|
| 2022
|
Pharmacokinetics, pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease..
Blood Advances.
2022
|
|
| 2022
|
An evaluation of cardiopulmonary endurance and muscular strength in adults living with sickle cell disease.
British Journal of Haematology.
199:597-602.
2022
|
|
| 2022
|
Hemorrhagic Stroke in Children and Adults with Sickle Cell Anemia: The Post-STOP Cohort.
Stroke.
53:E463-E466.
2022
|
|
| 2022
|
What does it mean to be affiliated with care?: Delphi consensus on the definition of “unaffiliation” and “specialist” in sickle cell disease.
PLoS One.
17.
2022
|
|
| 2022
|
Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study.
The hematology journal : the official journal of the European Haematology Association / EHA.
107:2466-2473.
2022
|
|
| 2022
|
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Blood.
140:1470-1481.
2022
|
|
| 2022
|
Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease.
American Journal of Hematology.
97:E318-E320.
2022
|
|
| 2022
|
Barriers and Facilitators to Chronic Red Cell Transfusion Therapy in Pediatric Sickle Cell Anemia
2022
|
|
| 2022
|
Confirmation of the utility of the Wells’ Score for pulmonary embolism in patients with sickle cell disease.
Journal of Thrombosis and Thrombolysis.
54:193-196.
2022
|
|
| 2022
|
Treatment-related Correlates of Growth in Children with Sickle Cell Disease in the DISPLACE Cohort.
Journal of Pediatric Hematology/Oncology.
44:249-254.
2022
|
|
| 2022
|
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.
American Journal of Hematology.
97:603-612.
2022
|
|
| 2022
|
Perspectives of individuals with sickle cell disease on barriers to care.
PLoS One.
17.
2022
|
|
| 2022
|
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Blood Advances.
6:1243-1254.
2022
|
|
| 2022
|
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
New England Journal of Medicine.
386:617-628.
2022
|
|
| 2022
|
GRNDaD: big data and sickle cell disease..
Blood Advances.
6:1088.
2022
|
|
| 2022
|
Acute myeloid leukemia case after gene therapy for sickle cell disease.
New England Journal of Medicine.
386:138-147.
2022
|
|
| 2021
|
Association Between Patent Foramen Ovale and Overt Ischemic Stroke in Children With Sickle Cell Disease.
Frontiers in Neurology.
12.
2021
|
|
| 2021
|
Gene therapy for sickle cell disease: where we are now?.
Hematology.
2021:174-180.
2021
|
|
| 2021
|
Gaps in the diagnosis and management of iron overload in sickle cell disease: a ‘real-world’ report from the GRNDaD registry.
British Journal of Haematology.
195:e157-e160.
2021
|
|
| 2021
|
Identifying barriers to evidence-based care for sickle cell disease: Results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.
BMJ Open.
11.
2021
|
|
| 2021
|
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
British Journal of Haematology.
195:e150-e153.
2021
|
|
| 2021
|
Which adults with sickle cell disease need an evaluation for pulmonary embolism?.
British Journal of Haematology.
195:447-455.
2021
|
|
| 2021
|
Improving Outcomes for Patients with Sickle Cell Disease in the United States: Making the Case for More Resources, Surveillance, and Longitudinal Data.
JAMA Health Forum.
2:E213467.
2021
|
|
| 2021
|
Annals On Call - Vascular Occlusive Crisis: Site of Care Matters.
ACP journal club.
174:OC1.
2021
|
|
| 2021
|
Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium.
PLoS One.
16.
2021
|
|
| 2021
|
American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantation.
Blood Advances.
5:3668-3689.
2021
|
|
| 2021
|
One small step for sickle cell disease: Many more to go.
ACP journal club.
174:1313-1314.
2021
|
|
| 2021
|
Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease.
International Journal of Laboratory Hematology.
43:O168-O170.
2021
|
|
| 2021
|
Kneeling was the first step for sickle cell disease.
ACP journal club.
174:1004-1005.
2021
|
|
| 2021
|
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
Journal of managed care & specialty pharmacy.
27:650-659.
2021
|
|
| 2021
|
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults with Sickle Cell Disease: A Randomized Clinical Trial.
Journal of the American Medical Association.
325:1513-1523.
2021
|
|
| 2021
|
Feasibility of an mHealth self-management intervention for children and adolescents with sickle cell disease and their families.
Translational Behavioral Medicine.
11:724-732.
2021
|
|
| 2021
|
Definity, an affinity for painful crisis: a case series describing vaso-occlusive pain crises in sickle cell patients undergoing echocardiogram with Definity contrast.
European Heart Journal: Case Reports.
5.
2021
|
|
| 2021
|
Emergency department utilization for sickle cell disease in st. Vincent and the grenadines.
The Pan African Medical Journal.
38.
2021
|
|
| 2021
|
Transcranial doppler screening in a current cohort of children with sickle cell anemia: Results from the DISPLACE Study.
Journal of Pediatric Hematology/Oncology.
2021
|
|
| 2020
|
Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium.
Pediatric Blood and Cancer.
67.
2020
|
|
| 2020
|
A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department.
Annals of Emergency Medicine.
76:S64-S72.
2020
|
|
| 2020
|
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.
American Journal of Hematology.
95:E239-E242.
2020
|
|
| 2020
|
Building access to care in adult sickle cell disease: Defining models of care, essential components, and economic aspects.
Blood Advances.
4:3804-3813.
2020
|
|
| 2020
|
Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease.
Blood.
136:623-626.
2020
|
|
| 2020
|
Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry.
Orphanet Journal of Rare Diseases.
15.
2020
|
|
| 2020
|
Perceptions of US Adolescents and Adults with Sickle Cell Disease on Their Quality of Care.
JAMA Network Open.
3.
2020
|
|
| 2020
|
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.
Blood Advances.
4:2058-2063.
2020
|
|
| 2020
|
Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium.
Pediatric Blood and Cancer.
67.
2020
|
|
| 2020
|
An unusual ultrasound appearance of renal hemosiderosis in acute sickle cell nephropathy.
Radiology Case Reports.
15:26-30.
2020
|
|
| 2020
|
Changes in Care Delivery for Children with Sickle Cell Anemia during the COVID-19 Pandemic.
Journal of Pediatric Hematology/Oncology.
2020
|
|
| 2020
|
Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease..
Therapeutic Advances in Hematology.
11:2040620720955000.
2020
|
|
| 2020
|
Development of a severity classification system for sickle cell disease.
ClinicoEconomics and Outcomes Research.
12:625-633.
2020
|
|
| 2020
|
Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease.
Clinical Pharmacology and Therapeutics.
107:140-146.
2020
|
|
| 2019
|
An approach to revising mHealth interventions for children and families: A case example in sickle cell disease.
Research in Nursing and Health.
42:483-493.
2019
|
|
| 2019
|
International differences in outpatient pain management: A survey of sickle cell disease.
Journal of Clinical Medicine.
8.
2019
|
|
| 2019
|
Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era.
American Journal of Hematology.
94:1335-1343.
2019
|
|
| 2019
|
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
Lancet Haematology.
6:e585-e596.
2019
|
|
| 2019
|
Diagnosis of Hemoglobin M Disease in a Toddler Presenting With Hypoxemia and Hemolysis.
Clinical Pediatrics.
58:1345-1348.
2019
|
|
| 2019
|
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3).
Contemporary Clinical Trials.
85.
2019
|
|
| 2019
|
A Phase 3 randomized trial of voxelotor in sickle cell disease.
New England Journal of Medicine.
381:509-519.
2019
|
|
| 2019
|
Health-related Quality of Life in Children with Sickle Cell Disease Undergoing Chronic Red Cell Transfusion Therapy.
Journal of Pediatric Hematology/Oncology.
41:307-312.
2019
|
|
| 2019
|
Childhood Hearing Loss in Patients With Sickle Cell Disease in the United States.
Journal of Pediatric Hematology/Oncology.
41:124-128.
2019
|
|
| 2019
|
Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.
British Journal of Haematology.
184:1058-1061.
2019
|
|
| 2019
|
Barriers to Pediatric Sickle Cell Disease Guideline Recommendations.
Global Pediatric Health.
6.
2019
|
|
| 2019
|
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
American Journal of Hematology.
94:55-61.
2019
|
|
| 2019
|
Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study.
British Journal of Haematology.
184:269-278.
2019
|
|
| 2018
|
The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease.
American Journal of Hematology.
93:E391-E395.
2018
|
|
| 2018
|
The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia.
Journal of Stroke and Cerebrovascular Diseases.
27:2897-2904.
2018
|
|
| 2018
|
Opioid utilization patterns in United States individuals with sickle cell disease.
American Journal of Hematology.
93:E345-E347.
2018
|
|
| 2018
|
Incomplete implementation of guideline-based stroke prevention therapy in sickle cell disease.
American Journal of Hematology.
93:E222-E224.
2018
|
|
| 2018
|
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).
Blood Advances.
2:1969-1979.
2018
|
|
| 2018
|
A phase 3 trial of l-glutamine in sickle cell disease.
New England Journal of Medicine.
379:226-235.
2018
|
|
| 2018
|
Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
Journal of Thrombosis and Thrombolysis.
45:512-515.
2018
|
|
| 2018
|
Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
Journal of Pain and Palliative Care Pharmacotherapy.
32:20-26.
2018
|
|
| 2018
|
Crizanlizumab.
Drugs of the Future.
43:489-499.
2018
|
|
| 2017
|
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases
2017
|
|
| 2017
|
Crizanlizumab in sickle cell disease.
New England Journal of Medicine.
376:1795-1796.
2017
|
|
| 2017
|
Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings from Get with the Guidelines-Stroke.
Stroke.
48:686-691.
2017
|
|
| 2017
|
Crizanlizumab for the prevention of pain crises in sickle cell disease.
New England Journal of Medicine.
376:429-439.
2017
|
|
| 2017
|
Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.
British Journal of Haematology.
176:300-308.
2017
|
|
| 2017
|
Newborn Screening for Sickle Cell Disease in St. Vincent and the Grenadines: Results of a Pilot Newborn Screening Program.
Global Pediatric Health.
4.
2017
|
|
| 2017
|
Prevalence of sickle cell disease among newborns in St Vincent and the Grenadines: A retrospective study
2017
|
|
| 2017
|
Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Thrombosis and Haemostasis.
117:580-588.
2017
|
|
| 2016
|
Transcranial doppler re-screening of subjects who participated in STOP and STOP II.
American Journal of Hematology.
91:1191-1194.
2016
|
|
| 2016
|
Assessing the immunogenic response of a single center's pneumococcal vaccination protocol in sickle cell disease.
Journal of Pediatric Hematology/Oncology.
38:e102-e106.
2016
|
|
| 2016
|
A multinational trial of prasugrel for sickle cell vaso-occlusive events.
New England Journal of Medicine.
374:625-635.
2016
|
|
| 2016
|
Validation of a low-cost paper-based screening test for sickle cell anemia.
PLoS One.
11.
2016
|
|
| 2016
|
Needs assessment for patients with sickle cell disease in South Carolina, 2012.
Public Health Reports.
131:108-116.
2016
|
|
| 2015
|
Validation of a novel point of care testing device for sickle cell disease.
BMC Medicine.
13.
2015
|
|
| 2015
|
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trial.
Biology of Blood and Marrow Transplantation.
21:900-905.
2015
|
|
| 2015
|
Multicenter COMPACT study of COMplications in Patients with sickle cell disease and utilization of iron Chelation Therapy.
Current Medical Research and Opinion.
31:513-523.
2015
|
|
| 2015
|
When is the optimal time to screen for chlamydia in adolescents and young adults with sickle cell disease?.
Clinical Pediatrics.
54:149-151.
2015
|
|
| 2015
|
Prasugrel in children with sickle cell disease: Pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
Journal of Pediatric Hematology/Oncology.
37:1-9.
2015
|
|
| 2014
|
Density-based separation in multiphase systems provides a simple method to identify sickle cell disease
2014
|
|
| 2014
|
A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea.
Journal of Pediatric Hematology/Oncology.
36.
2014
|
|
| 2013
|
A case of invasive Streptococcus pneumoniae in an afebrile adolescent with sickle cell disease.
Clinical Pediatrics.
52:1173-1175.
2013
|
|
| 2013
|
Management of sickle cell disease from childhood through adulthood.
Blood Reviews.
27:279-287.
2013
|
|
| 2013
|
A simple, rapid, low-cost diagnostic test for sickle cell disease
2013
|
|
| 2013
|
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.
Pediatric Blood and Cancer.
60:101-109.
2013
|
|
| 2013
|
Simple paper-based test for measuring blood hemoglobin concentration in resource-limited settings.
2013
|
|
| 2012
|
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Blood.
119:5989-5995.
2012
|
|
| 2011
|
Posterior fossa syndrome after surgical removal of a pineal gland tumor.
Pediatric Neurology.
45:417-419.
2011
|
|
| 2011
|
A child with Wegener's granulomatosis and severe hemophilia A: Interplay of disease processes.
Clinical Pediatrics.
50:767-771.
2011
|
|
| 2009
|
Downsizing to resectabilty of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy.
Journal of Pediatric Surgery.
44.
2009
|
|
| 2008
|
Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates.
Clinical Cancer Research.
14:3942-3947.
2008
|
|
